Webinar going down Friday, March 26 at 10 a.m. EDT
BOULDER, Colorado, March 5, 2021 (GLOBE NEWSWIRE) – Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical firm targeted on the event of progressive and differentiated prescribed drugs for the therapy of debilitants pores and skin ailments, at present introduced that it’ll host a Key Opinion Chief (“KOL”) webinar within the Hyperhidrosis (Extreme Sweating) market on Friday, March 26, 2021 at 10:00 a.m. EDT.
This webinar will embrace displays by hyperhidrosis specialists Adam Friedman, MD, The George Washington College Faculty of Medication & Well being Sciences, and Joel L. Cohen, MD, AboutSkin Dermatology, who will present an outline of hyperhidrosis by means of the eyes of ‘a affected person and clinician prognosis. The 2 dermatologists will focus on the unmet want that exists in hyperhidrosis, the present therapy panorama and the unfavorable impacts on the standard of lifetime of pediatric and grownup sufferers. Drs. Friedman and Cohen shall be out there to reply questions after the official displays.
Robert Brown, CEO of Brickell, can even present an organization replace. Brickell’s lead analysis product candidate, sofpironium bromide, is a brand new chemical entity that’s at the moment being evaluated in a pivotal Part 3 scientific program in the USA as the perfect potential therapy for the therapy of major axillary hyperhidrosis. (armpit). Brickell plans to launch key information from this Part 3 scientific program within the fourth quarter of 2021.
To register for the webinar, please click on right here.
All business and funding professionals are welcome to attend the occasion, which shall be accessible through a webcast posted within the Buyers part of the Brickell web site at https://ir.brickellbio.com/events-presentations. In case you are unable to observe this stay streamed occasion, a replay shall be out there on the Brickell web site within the Buyers part after the occasion and archived for about 90 days.
Adam Friedman, MD, FAAD is Professor and Appearing Chair of Dermatology, as Director of the Residency Program, Director of Translational Analysis and Director of the Supporting Oncodermatology Program within the Division of Dermatology on the George Washington College Faculty of Medication & Well being Sciences. Dr. Friedman accomplished his undergraduate coaching on the College of Pennsylvania and graduated with Distinction in Dermatology Analysis from the Albert Einstein Faculty of Medication in New York Metropolis. He accomplished his internship at New York Hospital Queens and returned to Einstein Faculty for his residency in dermatology, the place he was appointed chief resident in his ultimate 12 months. Dr Friedman joined the school at Einstein Faculty after graduating from 2010 to 2015, throughout which era he was Director of Dermatology Analysis, Director of the Translational Analysis Fellowship and Affiliate Director of the Program.
Dr Friedman is at the moment investigating new nanotechnologies that permit managed and sustained supply of a broad spectrum of physiologically and medically related molecules, with an emphasis on the therapy of infectious ailments, acceleration of wound therapeutic, modulation immune system and the correction of vascular dysfunctions. He holds a number of patents derived from this analysis and has printed over 170 articles / chapters and a pair of textbooks on his analysis in addition to a wide range of scientific areas in dermatology with an emphasis on rising medical therapies. He has acquired quite a few awards such because the Younger Chief Award from the American Dermatologic Affiliation, the American Society for Dermatologic Surgical procedure Slicing Edge Analysis Award, the Elle Magnificence Genius Award 2017, the Journal of Medication Improvements in Residency Instructing Award 2018, the La Roche Posay North American Basis Analysis Award, and has been on Washington’s checklist of high physicians since 2017.
Joel L. Cohen, MD is an internationally famend professional in medical dermatology, pores and skin most cancers and aesthetics. Dr Cohen has been named one of many US Information and World Report’s High Dermatologists, one in all Citadel Connelly’s High Regional Physicians (2013-2020), and has been voted by his friends as one in all Denver’s High Physicians. in 5280 Journal. NEW occasions (together with listings for beauty procedures in addition to dermatology). He’s licensed by the American Board of Dermatology and accomplished a Fellowship in Dermatologic and Aesthetic Surgical procedure in Mohs Micrographic Surgical procedure (for the therapy of facial pores and skin cancers), Pores and skin Oncology, Facial Reconstruction, Surgical procedure aesthetic and laser surgical procedure.
He’s the director of AboutSkin Dermatology and DermSurgery in Greenwood Village and Lone Tree, Colorado. Dr. Cohen was elected as a Nationwide Teacher in Dermatologic Surgical and Aesthetic Procedures by the American Society of Dermatologic Surgical procedure (ASDS) for the ASDS Preceptorship Program and the American Society of Lasers in Medication and Surgical procedure (ASLMS) for the Program of ASLMS preceptorship. . He’s the co-director of the fellowship for the ASDS Dermatologic Surgical procedure Colorado Fellowship. He’s on the instructing college of a number one college dermatology program as a Medical Affiliate Professor on the College of California, Irvine. As well as, Dr. Cohen is the recipient of the Affected person Selection Award from 2010 to 2019. He was additionally the recipient of the ASDS Public Service Award, the ASCDAS Distinguished Service Award, the ASDS Touring Mentorship and Instructing Award and the ASDS Excellence in Training Award. In 2018, he acquired the Humanitarian of the Yr award from the Melanoma Analysis Basis.
Brickell Biotech, Inc. is a clinical-stage pharmaceutical firm targeted on the event of progressive and differentiated prescribed drugs for debilitating pores and skin ailments, specializing in its major lively, sofpironium bromide for the therapy of hyperhidrosis. Brickell’s administration staff and board of administrators convey intensive expertise in product growth and international commercialization, having held management positions in giant international pharmaceutical corporations and biotechnology corporations which have developed and / or launched profitable merchandise, lots of that are distinguished and / or achieved iconic standing, reminiscent of Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s technique is to leverage this expertise to license, purchase, develop and commercialize progressive and differentiated prescription drugs that Brickell believes can succeed within the market and rework lives by assembly the wants of at the moment unmet sufferers. . For extra data go to https://www.brickellbio.com.
Warning concerning forward-looking statements
Any assertion made on this press launch concerning future monetary, enterprise and / or analysis and scientific efficiency, circumstances, plans, prospects, tendencies or methods and different comparable issues, together with, with out exception y restrict, the timing, scope, design, progress and / or outcomes of ongoing and future scientific trials, mental property rights, together with the validity, length and enforceability thereof, the anticipated timing and / or outcomes of regulatory submissions and approvals, and prospects for commercializing any of Brickell’s product candidates, or analysis collaborations with, or actions of, its companions, together with in Japan, in the USA or some other nation, are forward-looking statements inside the that means of the USA Non-public Securities Litigation Reform Act of 1995. As well as, when or if they’re used on this press or the webinar that’s the topic of this press launch, the phrases “might”, “might”, “ought to”, “anticipate”, “imagine”, “estimate”, “foresee”, “intend”, “Plan”, “anticipate”, “potential”, “anticipate” and comparable expressions and variations thereof, with respect to Brickell, Kaken or any of Brickell’s companions, might establish forward-looking statements. Brickell cautions that these forward-looking statements are topic to many assumptions, dangers and uncertainties, which change over time, typically quickly and in unexpected methods. Necessary elements which will trigger precise outcomes to vary materially from outcomes mentioned in forward-looking statements or historic expertise embrace dangers and uncertainties, together with, with out limitation, the flexibility to acquire ample funding for advance product growth, the flexibility to take care of and implement mental property rights. , potential delays for any cause in product growth, regulatory modifications, provide chain disruptions, unanticipated calls for for money sources, any enterprise disruption attributable to the present COVID pandemic- 19, interruptions, disruption or incapacity of Kaken to provide and market the product in Japan, or acquire or preserve ample pricing or reimbursement, the results of Brickell’s US pivotal Part 3 sofpironium bromide program and different dangers related to the event, acquiring regulatory approval and commercialization of product candidates. Additional data on the elements and dangers that would trigger precise outcomes to vary from forward-looking statements is contained within the paperwork filed by Brickell with the USA Securities and Change Fee (SEC), out there at ‘tackle https://www.sec.gov (or on https://www.brickellbio.com). Ahead-looking statements signify Brickell’s estimates as of the date hereof solely, and Brickell expressly disclaims any obligation or obligation to replace any forward-looking statements.
Brickell investor contact: